
|Podcasts|July 5, 2023
Achieving Durable Clinical Response with Targeted Treatments for Vitiligo
Listen
0:00 / 0:00
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Advertisement
0:53 Quality of life impact of vitiligo
2:55 Pathogenesis of vitiligo
5:08 Approaches to vitiligo treatment
8:30 Mechanism of JAK inhibitors
10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib
14:15 Variation in repigmentation with vitiligo
17:20 Safety of topical ruxolitinib
21:00 Data from the long-term extension trial of ruxolitinib
25:75 Achieving meaningful treatment response in vitiligo
30:15 Investigational biomarkers and treatments for vitiligo
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5


























































